{"abstract": "A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen.", "web_url": "https://dealbook.nytimes.com/2014/05/15/the-right-price-for-astrazenecas-stock/", "snippet": "A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen.", "lead_paragraph": "Investors are putting a lot of faith in Pfizer succeeding in its $100 billion-plus quest to acquire British pharmaceuticals rival AstraZeneca. The right price for the target\u2019s share price can be seen as the weighted average of two possible outcomes \u2013 a sale to Pfizer or a standalone future. A new Breakingviews calculator shows why the market seems to think a transaction will probably happen.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg", "height": 900, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 900}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-jumbo.jpg", "height": 1024, "width": 683, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-superJumbo.jpg", "height": 2048, "width": 1366, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "The Right Price for AstraZeneca\u2019s Stock", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Stocks and Bonds", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}], "pub_date": "2014-05-15T18:54:48+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Christopher Hughes", "person": [{"firstname": "Christopher", "middlename": null, "lastname": "Hughes", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d87bc7ef-a7d0-577b-869b-6b268df07149", "word_count": 360, "uri": "nyt://article/d87bc7ef-a7d0-577b-869b-6b268df07149"}